

Regimen Reference Order – LYMP – brentuximab vedotin

ARIA: LYMP - [brentuximab vedotin]

Planned Course: Every 21 days for a maximum of 16 cycles
Indication for Use: Hodgkin Lymphoma (Relapsed/Refractory or Consolidation post autologous stem cell transplant)
 OR
 Anaplastic Large Cell Lymphoma Relapsed

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$

❖ **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP – brentuximab vedotin

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
acetaminophen	650 mg	Orally 30 minutes prior to brentuximab vedotin
dexamethasone	12 mg	IV in normal saline 50 mL over 15 minutes
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes
brentuximab vedotin	1.8 mg/kg	IV in normal saline 100 mL over 30 minutes <i>Concentration dependent drug. Pharmacy will adjust diluent volume to ensure drug stability</i>

Maximum dose of brentuximab vedotin is 180 mg

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See LYMP DSG – Dose Banding document for more information

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

- CBC, biochemistry every cycle as per physician order
- Assess for neuropathy prior to every cycle
- Full vital signs (temperature, heart rate, respiration, blood pressure and O₂ saturation) prior to each dose of brentuximab vedotin and as clinically indicated
- No observation period is required
- Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- brentuximab vedotin can cause peripheral neuropathy